Previous research has demonstrated that targeting the CtBP1–FOXM1 complex with small molecules represents a promising approach to overcoming MDR1-mediated chemoresistance in osteosarcoma cancer stem cells [36]. The gene discussed is FOXM1; the disease is osteosarcoma.